Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Viking Therapeutics, Inc. (VKTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update -- VANQUISH Phase 3 Trials for Subcutaneous VK2735 in Obesity Continue to Advance -- -- SUNRISE Phase 3 Trials for Oral VK2735 Initiated -- -- Positive Top-Line Results Ann
How this was made
The 30-second read
Why it matters
The report provides fresh quantitative data on cash resources and qualitative updates on multiple Phase 3 programs, which are material for valuation.
Market read
First‑time disclosure of trial initiations and cash position offers actionable insight for traders focused on biotech earnings and pipeline news.
What to watch
Potential competition from other GLP‑1/GIP agents and regulatory timelines could temper upside.
Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Viking advanced four Phase 3 VK2735 trials, reported positive maintenance-study data and ended the quarter with $960 million in cash, cash equivalents and short-term investments following financing. These development and liquidity advances were accompanied by a wider net loss of $183.2 million, as research and development and general and administrative spending increased substantially.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, three months ended September 30, 2026GAAP | $ — | – | – |
| Research and development expenses, three months ended September 30, 2026GAAP | $166.8M | – | – |
| General and administrative expenses, three months ended September 30, 2026GAAP | $20.3M | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | 187.1M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −187.1M | – | – |
| Interest income, net, three months ended September 30, 2026GAAP | 4.01M | – | – |
| Interest expense, net, three months ended September 30, 2026GAAP | −88K | – | – |
| Total other income, net, three months ended September 30, 2026GAAP | 3.93M | – | – |
| Net loss, three months ended September 30, 2026GAAP | $183.2M | – | – |
| Basic and diluted net loss per share, three months ended September 30, 2026GAAP | $1.55 per share | – | – |
| Comprehensive loss, three months ended September 30, 2026GAAP | −$183.7M | – | – |
| Weighted-average shares used to compute basic and diluted net loss per share, three months ended September 30, 2026GAAP | 118.0M | – | – |
| Revenue, nine months ended September 30, 2026GAAP | $ — | – | – |
| Research and development expenses, nine months ended September 30, 2026GAAP | $432.7M | – | – |
| General and administrative expenses, nine months ended September 30, 2026GAAP | $51.1M | – | – |
| Total operating expenses, nine months ended September 30, 2026GAAP | 483.8M | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | −483.8M | – | – |
| Interest income, net, nine months ended September 30, 2026GAAP | 14.36M | – | – |
| Interest expense, net, nine months ended September 30, 2026GAAP | −88K | – | – |
| Total other income, net, nine months ended September 30, 2026GAAP | 14.30M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | $469.5M | – | – |
| Basic and diluted net loss per share, nine months ended September 30, 2026GAAP | $4.03 per share | – | – |
| Comprehensive loss, nine months ended September 30, 2026GAAP | −$471.6M | – | – |
| Weighted-average shares used to compute basic and diluted net loss per share, nine months ended September 30, 2026GAAP | 116.6M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
2027 and 2028 clinical-development milestones outlook
- NoteVANQUISH Phase 3 studies are expected to be completed in 2027.
- NoteVANQUISH extension-study results are anticipated to be available in 2028.
- NotePart 2 maintenance dosing study results are expected to be available in 2027.
- NoteThe company expects to complete the VK3019 SAD study later this quarter and initiate a 4 week MAD study of VK3019 in 1Q27.
What drove it
- Research and development expense increased primarily because of planned and ongoing clinical studies, manufacturing for drug candidates, stock-based compensation, salaries and benefits, and third-party consultants.
- General and administrative expense increased primarily because of legal and patent services, third-party consultants, stock-based compensation, and salaries and benefits.
- VANQUISH-1 enrolled approximately 4,500 patients within approximately five months of initiation, while VANQUISH-2 enrolled approximately 1,000 patients within approximately 9 months of initiation.
- SUNRISE-1 and SUNRISE-2 are each targeting enrollment of 560 adults and will evaluate once-daily oral VK2735 doses for 68 weeks.
- Part 1 maintenance-study participants maintained on 17.5 mg weekly reached approximately 22% weight loss from baseline through the 33 week study period.
Concerns
- Viking reported no revenue and recorded a net loss of $183.2 million for the third quarter.
- Research and development expenses were $166.8 million, compared to $90.0 million for the same period in 2025.
- General and administrative expenses were $20.3 million, compared to $8.6 million for the same period in 2025.
- The company stated that prior clinical and preclinical results may not be replicated and that development activities and clinical trials are subject to risks concerning success, cost and timing.
What to watch
- Completion of the VANQUISH Phase 3 studies in 2027.
- Commencement of VANQUISH extension studies in 1Q27 and availability of their results in 2028.
- Results from Part 2 of the VK2735 maintenance dosing study in 2027.
- Completion of the VK3019 SAD study later this quarter and initiation of the 4 week MAD study in 1Q27.
- Progress of SUNRISE-1 and SUNRISE-2, the oral VK2735 Phase 3 trials.
Balance sheet and cash flow
- Cash, cash equivalents and short-term investments were $960 million at September 30, 2026, compared to $706 million as of December 31, 2025.
- Cash and cash equivalents were $677,609 (In thousands) at September 30, 2026, compared to $165,810 (In thousands) at December 31, 2025.
- Short-term investments – available-for-sale were $282,204 (In thousands) at September 30, 2026, compared to $539,929 (In thousands) at December 31, 2025.
- Concurrent upsized public offerings of common stock and convertible senior notes generated gross proceeds of approximately $575.0 million and aggregate net proceeds of approximately $550 million.
- Convertible Notes were $250,656 (In thousands) at September 30, 2026, compared to $ — at December 31, 2025.
- Total assets were $977,167 (In thousands) at September 30, 2026, compared to $715,729 (In thousands) at December 31, 2025.
- Total liabilities were $388,567 (In thousands) at September 30, 2026, compared to $76,667 (In thousands) at December 31, 2025.
Analysis
Viking remains a clinical-stage company with no reported revenue, and the quarter reflects a substantial escalation in development spending. Third-quarter research and development expense was $166.8 million versus $90.0 million in the corresponding 2025 period, while general and administrative expense was $20.3 million versus $8.6 million. The resulting GAAP net loss was $183.2 million, or $1.55 per share, compared with a net loss of $90.8 million, or $0.81 per share. For the nine months, the GAAP net loss was $469.5 million, or $4.03 per share.
The operating build is tied to a broad obesity development program. Both subcutaneous VK2735 VANQUISH Phase 3 studies continued to advance, with the company expecting completion in 2027. Viking also initiated the SUNRISE oral Phase 3 program. SUNRISE-1 and SUNRISE-2 each target enrollment of 560 adults, and participants will receive once-daily treatment for 68 weeks. The company presents the parallel oral and subcutaneous programs, as well as potential less-frequent maintenance dosing, as key elements of VK2735's product profile.
Part 1 of the VK2735 maintenance study supplied the principal clinical update. The filing said that weight loss at Week 21 ranged from approximately 16% to approximately 19%, compared with approximately 0% for placebo. At Week 33, mean weight loss retained ranged from 83% to 97% among every-other-week cohorts and from 82% to 90% among monthly cohorts, compared with 61% for placebo. The 17.5 mg weekly exploratory cohort reached approximately 22% weight loss from baseline through the 33 week period. Part 2, which adds daily oral and additional subcutaneous maintenance regimens, is underway and is expected to report results in 2027.
Liquidity improved materially through September financings. Viking reported gross proceeds of approximately $575.0 million and aggregate net proceeds of approximately $550 million from concurrent common-stock and convertible-note offerings. Cash, cash equivalents and short-term investments were $960 million at quarter-end, compared with $706 million at December 31, 2025. The balance sheet also reported Convertible Notes of $250,656 (In thousands), while shares issued and outstanding increased to 127,521,229 from 114,793,067.
The central items to monitor are clinical execution and expense intensity. The company expects VANQUISH extension studies to commence in 1Q27, Part 2 maintenance-study results in 2027, and VANQUISH extension results in 2028. It also expects to complete the VK3019 SAD study later this quarter and start a 4 week MAD study in 1Q27. The financing supports these programs and commercialization preparations, but the widening loss and increased operating expense make the pace and cost of the Phase 3 programs consequential.
Not in the filing
stated, not guessed- Non-GAAP financial metrics were not reported.
- Gross profit and gross margin were not reported.
- Segment revenue and segment results were not reported.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Share repurchases and dividends were not reported.
- Financial revenue, gross-margin, operating-expense, or tax-rate guidance was not reported.
- Prior-quarter comparisons for reported income-statement metrics were not reported.
- Percentage year-over-year changes for the reported financial line items were not reported.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Viking Therapeutics (VKTX) disclosed its Q3 2026 financials and pipeline milestones via a SEC Form 8‑K.
Ticker impact
VKTX filed an 8‑K reporting Q3 2026 results, a $960 M cash balance and the initiation of Phase 3 SUNRISE oral trials for VK2735.
likely upward pressure as investors price in new Phase 3 data and ample runway.
First‑report of sizable cash and new Phase 3 trial start are material catalysts for a clinical‑stage biotech.
Market effects
Strengthens the obesity‑treatment subsector and may boost peer biotech valuations.
U.S. biotech market sees modest uplift from the cash raise and trial progress.
Limited to biotech investors; no broad market effect.
Counterpoint
If trial data later underperform, the cash runway may not offset dilution from the recent offering.
Key entities
- companyViking Therapeutics, Inc.
Clinical‑stage biotech developing obesity treatments.
